Abiomed presents Impella PROTECT II study benefits in PCI at ACC and i actually2 Summit Abiomed.

The initial research was powered at 80 percent with the intended last population of 654 individuals. The interim report included the 50 percent mark and final evaluation included yet another 19 percent of patients. The pre-specified roll-in subject matter analysis demonstrated that, without the 1st patient in both hands, Impella was significantly better at 90 days.. Abiomed presents Impella PROTECT II study benefits in PCI at ACC and i actually2 Summit Abiomed, Inc. , a leading provider of breakthrough heart support technologies, announced the final results from the PROTECT II study today, presented by William O’Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American University of Cardiology’s 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.5 at 90 days..

AACN invites nurses, additional healthcare professionals to 2014 National Teaching Institute & Critical Care Exposition The American Association of Critical-Treatment Nurses invites nurses and other healthcare professionals who look after high acuity and critically ill patients and their families to its 2014 National Teaching Institute & Critical Care Exposition in Denver, May 19-22, with preconferences Might 17-18. The premier annual event for critical care nursing, NTI presents hundreds of sessions to improve clinical practice, affected person outcomes and the bottom line with a thorough system that incorporates the best evidence-based education.